About Protea Biosciences Group (OTCMKTS:PRGB)
Protea Biosciences Group, Inc. is a molecular information company. The Company is engaged in developing and commercializing life science technologies, products and services to identify the molecules that are produced by living cells and all life forms. It also offers a platform technology, Laser Ablation Electrospray Ionization (LAESI), which enables the direct analysis, mapping and display of molecular information in living cells and tissue samples. The Company's commercial development is centered in three business lines: Molecular Information Services, LAESI Instruments, Software and Consumables, and Molecular Diagnostics and Clinical Research. Its services enable the identification and quantitation of both small molecules (lipids and metabolites) and large molecules (proteins) and the services portfolio, inclusive of mass spectrometry imaging (MSI), proteomics, metabolomics, lipidomics and bioinformatics. Its clients include pharmaceutical, chemical and biotechnology companies.
Industry, Sector and Symbol
Trailing P/E Ratio-0.00484764542936288
Forward P/E RatioN/A
Sales & Book Value
Annual Sales$2.45 million
Price / Sales0.11
Price / CashN/A
Book Value($4.34) per share
Price / Book-0.01
Return on EquityN/A
Return on Assets-805.49%
Protea Biosciences Group (OTCMKTS:PRGB) Frequently Asked Questions
What is Protea Biosciences Group's stock symbol?
Protea Biosciences Group trades on the OTCMKTS under the ticker symbol "PRGB."
How were Protea Biosciences Group's earnings last quarter?
Protea Biosciences Group Inc (OTCMKTS:PRGB) issued its earnings results on Tuesday, November, 18th. The company reported ($0.07) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.05) by $0.02. The company earned $0.52 million during the quarter, compared to the consensus estimate of $0.46 million. View Protea Biosciences Group's Earnings History.
Who are some of Protea Biosciences Group's key competitors?
Some companies that are related to Protea Biosciences Group include Baxano Surgical (BAXSQ), Imris (IMRSQ), Savient Pharmaceuticals (SVNTQ), UniTek Global Services (UNTKQ), DS Healthcare Group (DSKX), Corinthian Colleges (COCOQ), International Shipholding (ISHCQ), Echo Therapeutics (ECTE), Kid Brands (KIDB), diaDexus (DDXS), Cache (CACH), Gordmans Stores (GMANQ), Velti (VELTF), NephroGenex (NRXGQ), School Specialty (SCHSQ), Local (LOCMQ), Circle Star Energy (CRCL) and Gasfrac Energy Svs (GSFVF).
Who are Protea Biosciences Group's key executives?
Protea Biosciences Group's management team includes the folowing people:
- Matthew Powell Ph.D., , Chief Scientific Officer, Vice President - Research & Development (Age 40)
- Stanley Hostler, Vice President, Secretary, Director (Age 87)
- Josiah T. Austin, Independent Director (Age 68)
- Leonard Harris, Independent Director (Age 79)
- Edwin S Roberson, Independent Director (Age 70)
- Scott Segal, Independent Director (Age 60)
How do I buy Protea Biosciences Group stock?
Shares of Protea Biosciences Group can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Protea Biosciences Group's stock price today?
One share of Protea Biosciences Group stock can currently be purchased for approximately $0.04.
How big of a company is Protea Biosciences Group?
Protea Biosciences Group has a market capitalization of $81,800.00 and generates $2.45 million in revenue each year. The company earns $-15,640,000.00 in net income (profit) each year or ($7.22) on an earnings per share basis. Protea Biosciences Group employs 25 workers across the globe.
How can I contact Protea Biosciences Group?
Protea Biosciences Group's mailing address is 1311 Pineview Dr Ste 501, MORGANTOWN, WV 26505-3276, United States. The company can be reached via phone at +1-304-2922226.
MarketBeat Community Rating for Protea Biosciences Group (PRGB)MarketBeat's community ratings are surveys of what our community members think about Protea Biosciences Group and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Protea Biosciences Group (OTCMKTS:PRGB) Analyst Ratings History
No equities research coverage for this company has been tracked by MarketBeat
Protea Biosciences Group (OTCMKTS:PRGB) Earnings History and Estimates Chart
Protea Biosciences Group (OTCMKTS PRGB) Earnings History by Quarter
(Earnings results data provided by Zacks Investment Research)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|11/18/2014||($0.05)||($0.07)||$0.46 million||$0.52 million||View||N/A|
Protea Biosciences Group (OTCMKTS:PRGB) Earnings Estimates
No earnings estimates for this company have been tracked by MarketBeat.com
Dividend History for Protea Biosciences Group (OTCMKTS:PRGB)
No dividend announcements for this company have been tracked by MarketBeat.com
Protea Biosciences Group (OTCMKTS PRGB) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 31.90%
Institutional Ownership Percentage: 3.39%
Protea Biosciences Group (OTCMKTS PRGB) Insider Trades by Quarter
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Shares Held After Transaction||Details|
|11/3/2016||Stanley Hostler||Director||Buy||293,333||$0.08||$23,466.64|| |
|7/25/2016||Stephen C Turner||CEO||Buy||20,000||$0.15||$3,000.00||2,197,372|| |
|7/5/2016||Stephen C Turner||CEO||Buy||24,000||$0.15||$3,600.00||2,177,372|| |
Protea Biosciences Group (OTCMKTS PRGB) News Headlines
Protea Biosciences Group (OTCMKTS:PRGB) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Financials are not available for this stock.
Protea Biosciences Group (OTCMKTS PRGB) Stock Chart for Saturday, January, 20, 2018